

# SPMS Diagnosis: A Canadian Practice Audit

R. Vosoughi,<sup>1</sup> M. Baharnoori,<sup>2</sup> J. Bakker,<sup>3</sup> W. Berger,<sup>4</sup> A. Gagnon,<sup>5</sup> T. Lad,<sup>6</sup> R. Leckey,<sup>7</sup> S. McKenzie,<sup>8</sup> A. Morinville,<sup>9</sup> D. Rivest,<sup>10</sup> and G. Vorobeychik<sup>11</sup>

<sup>1</sup>St. Michael's Hospital, Toronto ON; <sup>2</sup>Kingston Health Sciences Centre, Kingston ON; <sup>3</sup>Red Deer Regional Hospital, Red Deer AB; <sup>4</sup>London ON; <sup>5</sup>Clinique Neuro-Outaouais, Gatineau QC; <sup>6</sup>Burlington ON; <sup>7</sup>Nova Scotia Health, Halifax NS; <sup>8</sup>Mississauga ON; <sup>9</sup>Novartis Pharmaceuticals Canada, Dorval, QC; <sup>10</sup>Clinique Neuro-Lévis, Lévis QC; <sup>11</sup>Fraser Health MS Clinic, Burnaby BC, CANADA



## Introduction

- An estimated 50% of relapsing-remitting multiple sclerosis (RRMS) patients will develop secondary-progressive disease (SPMS) within 15-20 years of MS onset; the average age at onset is 45 years (1,2).
- The lack of consensus on diagnostic criteria contributes to clinician uncertainty and a considerable diagnostic delay (3).

## Objective

- To examine the clinical characteristics of patients potentially transitioning from RRMS to SPMS as well as SPMS patients in the Canadian practice setting.


## Methods

- A retrospective chart review was completed in Canadian MS specialized centres and community neurology practices of MS patients who received their RRMS diagnosis 10 to 20 years ago and had a current EDSS of 3.0 to 6.5.

## Results

- Data were collected for 708 patients at 15 centres (59% from 10 MS clinics, 41% from 5 community practices) (Figure 1).


Figure 1. Overall population (n=708).



Abbreviations: RRMS, relapsing-remitting multiple sclerosis; SPMS, secondary-progressive multiple sclerosis

- In the overall population, the majority were aged >50 years (58%). The average duration of MS was 15.2 years (range 13.3-17.1 years).
- The SPMS group (n=223) was older (74% aged >50 years vs. 49%), had a higher current Expanded Disability Status Scale (EDSS) score (mean 5.6 vs. 3.9) and a longer time from MS diagnosis (mean 16.1 vs. 14.7 years) compared to the RRMS group (n=485) (Figure 2).

Figure 2. General characteristics by diagnosis.



Abbreviations: RRMS, relapsing-remitting multiple sclerosis; SPMS, secondary-progressive multiple sclerosis

## Disease activity

- The proportion of patients with relapses was higher in the RRMS group vs. the SPMS group (22% vs. 16%) whereas the proportion of patients with new/expanding MRI lesions was lower (29% vs. 37%) (Table 1). A higher proportion of SPMS vs. RRMS patients had not undergone MRI within the past 2 years (19% vs. 6%).

Table 1. Evidence of disease activity in last 2 years by diagnosis.

Parameter	RRMS (n=485)	SPMS (n=223)
Change in EDSS	0.42	0.71
% of patients with relapses	22%	16%
% of patients with MRI	94%	81%
% of patients with MRI who had MRI activity	29%	37%
% of patients on DMT	84%	47%

Abbreviations: DMT, disease-modifying therapy; EDSS, Expanded Disability Status Scale; MRI, magnetic resonance imaging; RRMS, relapsing-remitting multiple sclerosis; SPMS, secondary-progressive multiple sclerosis

## MS-related symptoms

- Records were examined for the incidence of three MS-related symptoms. A higher proportion of SPMS patients had signs of cognitive impairment (49% vs. 26%), urinary incontinence/bladder dysfunction (84% vs. 43%) and sexual dysfunction (29% vs. 12%) compared to the RRMS group (Table 2). The incidence of sexual dysfunction was most likely underestimated as it was unknown in 63% of cases.


Table 2. Signs and symptoms in last 2 years by diagnosis.

Signs and symptoms	RRMS (n=485)	SPMS (n=223)
Cognitive dysfunction	26%	49%
Urinary/bladder dysfunction	43%	84%
Sexual dysfunction	12%	29%

## Medication use

- A majority of SPMS patients (119/223, 53%) were not receiving a disease-modifying therapy (DMT) (Figure 3); the most common DMTs were oral agents (29%) and first-line injectables (10%). In contrast, 84% of RRMS patients were currently on treatment; the most common DMTs were oral agents (40%) and monoclonal antibodies (28%).

Figure 3. Medication use according to diagnosis



## Comparison to real world data

- SPMS patients in Canada resembled non-active SPMS (naSPMS) patients from the Adelphi Real World MS Disease Specific Programme (DSP) (4) (Table 3)

Table 3. Comparison of Canadian results to Adelphi Real World MS DSP (4).

Characteristics	Adelphi <sup>4</sup>		Canada
	aSPMS (N=1889)	naSPMS (N=665)	SPMS (n=223)
EDSS score in the past 12 months, mean (SD)	4.6 (1.72) n=1463	5.2 (1.76) n=606	5.6
Change in EDSS score in the past 12 months, mean (SD)	0.43 (0.56)	0.20 (0.49)	0.71 (past 2 years)
Number of PLWMS with MRI conducted in the past 12 months (% non-missing)	1657 (87.7%)	390 (58.7%)	172/212 (81% in last 2 years)
Proportion of PLWMS not on any DMT (%)	23.4	45.1	53.4

Abbreviations: aSPMS, active SPMS; DMT, disease-modifying therapy; EDSS, Expanded Disability Status Scale; MRI, magnetic resonance imaging; naSPMS, non-active SPMS; PLWMS, people living with multiple sclerosis; SD, standard deviation; SPMS, secondary-progressive multiple sclerosis

## Conclusions

- SPMS is generally diagnosed about 16 years after MS onset when patients are aged >50 years and already have moderate-to-severe disability. SPMS patients are also more likely to be untreated. The above data could not determine if an SPMS diagnosis is delayed. Improved detection of worsening symptoms may enable earlier diagnosis of SPMS in younger patients before the onset of irreversible disability.

- In Canada, SPMS patients resembled naSPMS patients from the Adelphi data base.

## References

- Tremlett et al. Mult Scler 2008; 14:314-324.
- Tutuncu et al. Mult. Scler 2013; 19:188-198.
- Katz Sand et al. Mult. Scler 2014; 20:1654-1657.
- Giovannoni et al.ECTRIMS 2021, P001.

## Acknowledgments

The project was funded by Novartis Pharmaceuticals Canada, Montreal, Canada. Medical writing support was provided by Communications Lansdowne. The final responsibility for the content lies with the authors.

## Disclosures

**Dr. Reza Vosoughi** has participated in advisory committees for and/or received educational support and/or honoraria from Biogen Idec, EMD Serono, Genzyme, Novartis, Alexion and Hoffmann-La Roche; and has received grants from CIHR and MHRC. **Dr. Moogeh Baharnoori** has received an educational grant, presenter honorarium or travel support from Novartis, Biogen, Alexion, Sanofi, EMD Serono, Teva Neuroscience, Hoffmann-La Roche, Pendopharm and Bristol Myers Squibb. **Dr. Jacqueline Bakker** has provided consultancy services and/or participated in advisory boards for Biogen, Teva, Serono, Sanofi, Hoffmann-La Roche, Pendopharm, and Novartis. **Dr. Warren Berger** has provided consultancy services and participated in advisory boards for Biogen, Bristol Myers Squibb, Hoffmann-La Roche, EMD Serono, Novartis, Sanofi Genzyme, McKesson and Merz Canada. **Dr. Alexis Gagnon** has participated in advisory boards and speaker bureaus for Novartis, Biogen, EMD Serono and Hoffmann-La Roche; and has been a local study principal investigator for Sanofi and Roche. **Dr. Tara Lad** has received educational grants and/or presenter honoraria from Bristol Myers Squibb, Hoffmann-La Roche, Biogen, Aralez, Genzyme, EMD Serono and Novartis. **Dr. Richard Leckey** has received honoraria and/or grants from Sanofi Genzyme, Novartis, AbbVie, Celgene, Alexion, Eli Lilly and Hoffmann-La Roche. **Dr. Stephen McKenzie** has received honoraria from Biogen, AbbVie and Novartis. **Dr. Anne Morinville** is an employee of Novartis Pharmaceuticals Canada Inc. **Dr. Donald Rivest** has no conflicts of interest to report. **Dr. Galina Vorobeychik** has received research support, educational grants and/or presenter honoraria from Alexion, Berlex, Biogen, Celgene, Genzyme, Hoffmann-La Roche, Sanofi, Serono, Novartis and Teva.

Copyright © 2022 Novartis Pharma AG. All rights reserved.

Poster presented at the 38<sup>th</sup> congress of the European Committee for Treatment and Research in Multiple Sclerosis, RAI Amsterdam, Amsterdam, Netherlands, 26<sup>th</sup> - 28<sup>th</sup> October, 2022.

Visit the web at: <https://bit.ly/ectrims2022>

Copies of this poster obtained through Quick Response (QR) code are for personal use only and may not be reproduced without written permission of the authors

Presenter email address: [reza.vosoughi@unityhealth.to](mailto:reza.vosoughi@unityhealth.to)



Scan this QR code to download a copy Poster